A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Two-Phase Crossover Study of the Metabolic Impact of Tenofovir Disoproxil Fumarate on HIV-1 Seronegative Healthy Adult Males.

Trial Profile

A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Two-Phase Crossover Study of the Metabolic Impact of Tenofovir Disoproxil Fumarate on HIV-1 Seronegative Healthy Adult Males.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2010

At a glance

  • Drugs Tenofovir disoproxil fumarate (Primary)
  • Indications HIV infections
  • Focus Pharmacodynamics
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Jan 2010 Results published in Antiviral Therapy.
    • 22 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top